Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /home/lycotecweb/9D60403L/htdocs/2019/wp-content/plugins/revslider/includes/operations.class.php on line 2758

Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /home/lycotecweb/9D60403L/htdocs/2019/wp-content/plugins/revslider/includes/operations.class.php on line 2762

Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /home/lycotecweb/9D60403L/htdocs/2019/wp-content/plugins/revslider/includes/output.class.php on line 3706
Pharmaceutical Pipeline - Lycotec Ltd.

Clinical Efficacy Trial Phase IIa

 

t-RSV Lycosome – treatment for Diabetic Foot Ulcer

DOWNLOAD

Proof-of-Concept Clinical Trial

 

GAL – treatment of chronic persistent Chlamydia infection

READ MORE

LYCOSTATIN - high potency statin with anti ox-LDL activity

READ MORE

LYCOFLAVON - treatment of insulin resistance

READ MORE

ID-LctPR-40 - prostate hyperplasia and cancer

READ MORE

PTC Lycosome - treatment of NAFLD / NASH and pancreatic steatosis

READ MORE

Pharmacokinetics and Pharmacodynamics

 

GA-Lct-40 – treatment of atherosclerotic vulnerable plaque

READ MORE

LycOmega – high potency Omega 3 for the treatment of elevated triglycerides and LDL

READ MORE

Monoclonal Antibody Therapy – pre-clinical

 

Monoclonal antibody, LycoMab, can be used as a vector to deliver and potentiate efficacy of pro-apoptotic lycopene to prostate cancer cells.

READ MORE

LycoStent(TM) - pre clinical

 

New class of molecules for prevention of restenosis of endovascular stents and vascular scaffolding.

Download LycoStent™ PDF

LYCOTEC NEWSLETTER

Subscribe now and receive publications newsletter from us!

 
 

© 2010 – 2019 Copyright Lycotec Limited. Registered in England and Wales No: 6527761.